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Which patients with moderate hypoxemia benefit 
from long-term oxygen therapy? ways forward
Magnus ekström1
Thomas Ringbaek2
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Hospital, Lund University, Lund, 
Sweden; 2Respiratory Department, 
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Abstract: Long-term oxygen therapy (LTOT) improves prognosis in patients with COPD and 
chronic severe hypoxemia. The efficacy in moderate hypoxemia (tension of arterial oxygen; on 
air, 7.4−8.0 kPa) was questioned by a recent large trial. We reviewed the evidence to date (five 
randomized trials; 1,191 participants, all with COPD). Based on the current evidence, the survival 
time may be improved in patients with moderate hypoxemia with secondary polycythemia or 
right-sided heart failure, but not in the absence of these signs. Clinically, LTOT is not indicated 
in moderate hypoxemia except in the few patients with polycythemia or signs of right-sided 
heart failure, which may reflect more chronic and severe hypoxemia.
Keywords: survival, oxygen therapy, hypoxemia, COPD
Introduction
Long-term oxygen therapy (LTOT) improved prognosis in patients with COPD and 
chronic severe hypoxemia in the NOTT and MRC randomized controlled trials (RCTs) 
conducted in the 1970s (n=290).1,2 Based on the inclusion criteria of these trials,1,2 the 
established indications for LTOT are chronic severe hypoxemia (tension of arterial 
oxygen [PaO
2
] on air #7.3 kPa) or moderate hypoxemia (7.4−8.0 kPa) with concur-
rent polycythemia (erythrocyte volume fraction [EVF] .0.54) or signs of right-sided 
heart failure or pulmonary hypertension.3 Chronicity was defined as the resting daytime 
hypoxemia at least 3 weeks apart despite optimal therapy of the underlying disease(s) 
and the patient being in stable clinical condition.2
LTOT is given to prolong survival, and published evidence pertains to patients 
with COPD.4,5 A recent Cochrane report found no evidence for benefit from LTOT 
on breathlessness or health-related quality of life in the absence of severe resting 
hypoxemia.6 Surveys from several countries report that ∼15%–45% of the patients 
on LTOT do not meet the hypoxemia criteria and that many patients on LTOT have 
moderate hypoxemia.7 The effect of LTOT on mortality in moderate hypoxemia has 
been questioned,4,8 most recently by the large Long-Term Oxygen Therapy Trial 
(LOTT; n=738).5 We aimed to evaluate the effect of LTOT on mortality to inform 
its clinical usefulness and research priorities in patients with COPD and moderate 
hypoxemia. We also aimed to identify trial characteristics that could explain the 
differences in outcomes between studies with focus on the required level and chronicity 
of hypoxemia.
Methods
We identified studies fulfilling all the inclusion criteria: RCT design; compared LTOT, 
defined as oxygen therapy prescribed $15 h/day, with air or no LTOT; included 
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patients with COPD and moderate hypoxemia; and reported 
outcome data on mortality. Trials were identified by search-
ing Medline using keywords (“oxygen therapy” or “LTOT”), 
reference lists of published Cochrane reports,4,6 recent clinical 
guidelines,3 and papers in the field5 up to May 19, 2017. 
Abstracts were screened against the eligibility criteria by 
Magnus Ekström. Data from full-text articles were extracted 
and cross-validated by both authors independently. Extracted 
data included study design, publication year, eligibility 
criteria, number of participants with moderate hypoxemia, 
study interventions, blinding, and findings. Disagreements 
were solved through consensus, and data were tabulated. 
Focus was on relating the difference in outcomes between 
studies to eligibility criteria including the required level and 
chronicity of hypoxemia. Meta-analysis was not performed 
due to heterogeneity in study designs and insufficient reported 
outcome data for people with moderate hypoxemia.
Results
After screening 9,075 records, a total of five RCTs1,2,5,8,10 
(1,191 participants) of the efficacy of LTOT on mortality 
were included (Table 1). All participants had COPD, and the 
majority were men. Current smokers were included in the 
MRC trial (52% in the oxygen group and 33% in the control 
group) and in the NOTT (38% smoked regularly at the time 
of the study), whereas smoking was a contraindication for 
participation in the other three trials. None of the trials were 
blinded (Table 1). Moderate resting hypoxemia was defined 
as a PaO
2
 (air) $7.4 kPa in all studies except LOTT where 
it was defined as a saturation using pulse oximetry (SpO
2
) 
of 89%−93%.
The number of participants with moderate hypoxemia 
was not separately reported in the NOTT and MRC trials. 
Moderate resting hypoxemia was present in all participants in 
the studies by Gorecka et al8 (n=135) and Haidl et al10 (n=28) 
and 419 of 738 participants (57%) in the LOTT.
LTOT prescribed 24 h/day decreased the mortality rate 
compared with oxygen only during the night in NOTT, and 
the effect was consistent between participants with PaO
2
 (air) 
above or below 6.9 kPa. More specific outcomes for the group 
with moderate hypoxemia were not reported in NOTT or 
MRC. In the subsequent three trials1,2,5 (n=582), there was no 
between-group difference in the mortality rate (Table 1).
In terms of eligibility criteria, participants were required 
to have stable hypoxemia across a defined time period in the 
NOTT (1 week), MRC (3 weeks), and in the trial by Gorecka 
et al (3 weeks). In the pilot study of Haidl et al,10 patients 
were included in the trial during a COPD exacerbation. In the T
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Table 2 effect of LTOT in relation to level of hypoxemia and 
signs of chronicity
Hypoxemia level With signs of 
chronicity
Without signs of 
chronicity
Severe hypoxemia 
(PaO2 #7.3 kPa)
LTOT indicated LTOT; triala
Moderate hypoxemia 
(PaO2 7.4–8.0 kPa)
Unclear; trialb LTOT not indicated
Notes: Signs of chronicity include secondary polycythemia (evF .0.54) or signs of 
right-sided heart failure or pulmonary hypertension. aLTOT may be provided based 
on the NOTT1 and MRC2 study. We suggest the need for an efficacy trial of LTOT 
in people with PaO2 .7.0 kPa without signs of chronicity. 
bUsefulness of LTOT was 
supported by NOTT but is questionable in light of the LOTT; an efficacy trial is 
needed.
Abbreviations: evF, erythrocyte volume fraction; LTOT, long-term oxygen therapy; 
LOTT, Long-Term Oxygen Therapy Trial; PaO2, tension of arterial oxygen.
challenged (Table 2). Trials are needed on the efficacy of 
LTOT in people with: 1) moderate hypoxemia and signs of 
chronicity, based on the LOTT;1 2) PaO
2
 7.0−7.4 kPa, given 
the recent negative data in moderate hypoxemia, especially if 
trials in moderate hypoxemia and signs of chronicity turn out 
to be negative. Trials should establish and require chronicity 
of the hypoxemia and, in addition to survival, evaluate effects 
on hospitalizations, breathlessness, and quality of life where 
data are insufficient or lacking in severe hypoxemia.1,2
Conclusion
There is no evidence that LTOT has beneficial effect on 
patients with moderate hypoxemia without signs of chronic 
hypoxemia, and more studies are needed to establish solid 
evidence-based criteria for LTOT.
Author contributions
ME contributed to concept and design. Both authors contrib-
uted toward data analysis, drafting and critically revising the 
paper, gave final approval of the version to be published, and 
agree to be accountable for all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen 
therapy in hypoxemic chronic obstructive lung disease: a clinical trial. 
Ann Intern Med. 1980;93(3):391–398.
2. Medical Research Council Working Party. Long term domiciliary 
oxygen therapy in chronic hypoxic cor pulmonale complicating chronic 
bronchitis and emphysema. Lancet. 1981;1(8222):681–686.
3. Hardinge M, Annandale J, Bourne S, et al; British Thoracic Society 
Home Oxygen Guideline Development Group; British Thoracic Society 
Standards of Care Committee. British Thoracic Society guidelines for 
home oxygen use in adults. Thorax. 2015;70(suppl 1):i1–i43.
4. Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for 
chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 
2005;4:CD001744.
LOTT, hypoxemia was assessed using pulse oximetry, not 
blood gases, and patients who had been hospitalized because 
of a COPD exacerbation or other acute conditions 30 days 
prior to screening were excluded. Signs of chronicity or more 
severe hypoxemia were required in people with moderate 
hypoxemia in the NOTT (edema, hematocrit $55%, or P 
pulmonale on ECG) and MRC trial (at least one episode of 
heart failure with ankle edema). Such signs of chronicity 
were not required in the three subsequent trials including 
the LOTT.
Discussion
The current evidence supports that LTOT does not improve 
the prognosis in patients with COPD and moderate hypox-
emia except in the few patients with polycythemia or signs 
of right-sided heart failure.
When considering the effect of LTOT, central factors 
are level of hypoxemia and its chronicity. The only trials 
showing a survival benefit of LTOT were the original NOTT 
and MRC trials that included patients with severe hypoxemia 
and patients with moderate hypoxemia together with signs 
of hypoxemia-related complications.1,2
It is also known that hypoxemia often is transient. 
About 30%–50% of hypoxemic patients initially classified 
as clinically stable did not fulfill the hypoxemia criteria at 
re-evaluation at 2–3 months.1,9 Levi-Valensi et al9 dem-
onstrated that 20% of those who still met the hypoxemia 
criteria at 1 month were no longer hypoxemic after 3 months. 
Similar improvement may be seen in patients with moder-
ate hypoxemia. After a 1−3 week re-evaluation period in 
the NOTT, only 203 (19%) of 1,043 screened patients were 
included, and 21% of exclusions were due to improved blood 
gases.1 The re-evaluation of blood gases and, in patients 
with moderate hypoxemia, the requirement of signs of pos-
sible hypoxemia complications is likely to have restricted 
inclusion in the NOTT and MRC study mainly to patients 
with underlying chronic and severe hypoxemia. The lack of 
such measures, except in the study by Gorecka et al,8 could 
partly explain the lack of effectiveness of LTOT in more 
recent trials that did not assess the chronicity of hypoxemia 
and highlight the importance of re-evaluating hypoxemia in 
clinical practice.5,10
Compared with patients in the NOTT and MRC trial, 
patients starting LTOT are now older and have more 
comorbidities,11,12 as well as improved treatment of COPD 
and comorbid conditions such as cardiovascular diseases. 
In light of this and the reviewed evidence to date, we pro-
pose that the current hypoxemia criteria of LTOT should be 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 3
0-
M
ay
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
235
Oxygen in moderate hypoxemia – ways forward
5. The Long-Term Oxygen Treatment Trial Research Group; Albert RK, 
Au DH, et al. A randomized trial of long-term oxygen for COPD with 
moderate desaturation. N Engl J Med. 2016;375(17):1617–1627.
6. Ekström M, Ahmadi Z, Bornefalk-Hermansson A, Abernethy A, 
Currow D. Oxygen for breathlessness in patients with chronic obstruc-
tive pulmonary disease who do not qualify for home oxygen therapy. 
Cochrane Database Syst Rev. 2016;11:CD006429.
7. Pepin JL, Barjhoux CE, Deschaux C, Brambilla C. Long-term oxygen 
therapy at home. Compliance with medical prescription and effective use 
of therapy. ANTADIR Working Group on Oxygen Therapy. Association 
Nationale de Traitement a Domicile des Insuffisants Respiratories. Chest. 
1996;109(5):1144–1150.
8. Gorecka D, Gorzelak K, Sliwinski P, Tobiasz M, Zielinski J. Effect of 
long-term oxygen therapy on survival in patients with chronic obstruc-
tive pulmonary disease with moderate hypoxaemia. Thorax. 1997;52(8): 
674–679.
 9. Levi-Valensi P, Weitzenblum E, Pedinielli J-L, Racineux J-L, Duwoos H. 
Three-month follow-up of arterial blood gas determinations in candi-
dates for long-term oxygen therapy. Am Rev Respir Dis. 1986;133(4): 
547–551.
 10. Haidl P, Clement C, Wiese C, Dellweg D, Kohler D. Long-term oxygen 
therapy stops the natural decline of endurance in COPD patients with 
reversible hypercapnia. Respiration. 2004;71(4):342–347.
 11. Crockett AJ, Cranston JM, Moss JR, Alpers JH. Survival on long-term 
oxygen therapy in chronic airflow limitation: from evidence to outcomes 
in the routine clinical setting. Intern Med J. 2001;31(8):448–454.
 12. Ahmadi Z, Sundh J, Bornefalk-Hermansson A, Ekström M. Long-term 
oxygen therapy 24 vs 15 h/day and mortality in chronic obstructive 
pulmonary disease. PLoS One. 2016;11(9):e0163293.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 3
0-
M
ay
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
